• Skip to main content

Plain Language Summaries

Standalone, citable summaries published in the Future Science Group journals written to be understood by a lay audience

  • How To Publish
  • How to Write Plain Language Summaries
  • Frequently Asked Questions
  • Publications
    • Animated Videos
    • Bladder, Kidney and Genitals
    • Brain and Nerves
    • Cancer
    • Diabetes and Metabolic Hormones
    • Eyes and Vision
    • Heart and Circulation
    • Infections
    • Inflammatory and Immune-related disorders
    • Mental Health
    • Muscle and Bone
    • Rare Diseases
    • Skin
    • Vaccines
  • Advisory Panel
  • Supporters
  • Blog
  • About Us
  • Contact Us

Aug 22 2022

Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer

The ongoing TALAPRO-2 study is looking at the combination of two medicines called talazoparib and enzalutamide as a first treatment in adult men with metastatic castration-resistant prostate cancer. This plain language summary provides an overview of the study protocol published in Future Oncology.

Read the full article here.

The original article on which this summary is based is called ‘Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design’ and was originally published in the journal Future Oncology. The original article can be read here.

  • Share on Twitter Share on Twitter
  • Share on Facebook Share on Facebook
  • Share on LinkedIn Share on LinkedIn

Written by Joanne Walker · Categorized: Bladder, Kidney and Genitals, Cancer · Tagged: clinical trial, enzalutamide, lay summary, metastatic castration-resistant prostate cancer, plain language summary, talazoparib

Copyright © 2023 · Plain Language Summaries · Terms and Conditions · Privacy Policy ·